Exela Pharma Sciences LLC – FDA 483, Nov 4, 2024

The provided document consists almost entirely of redacted information, indicated by '(b) (4)' markings. Consequently, specific details such as the company name, inspection dates, main violations or issues observed, and any required actions cannot be extracted. The unredacted portions only describe the general purpose of an FDA Form 483 and cite Section 704(b) of the Federal Food, Drug and Cosmetic Act (21 USC 374(b)). This section outlines that inspectors report conditions or practices indicating products may be adulterated or prepared under insanitary conditions. Without the specific details that have been redacted, a summary addressing the company, inspection specifics, and particular findings cannot be generated.